Finally, cell lines close to the breast cancer-specific HER2 archetype (tumors that over-expresses the erbB-2 receptor) are sensitive to herceptin, an erbB-2 inhibitor (Fig. 2h). Here, ERBB2 is linked to breast carcinoma.